Experienced in Kaposi Sarcoma

Dr. Onyema E. Ogbuagu

Infectious Disease
Yale University
800 Howard Ave, 
New Haven, CT 
Experienced in Kaposi Sarcoma
Yale University
800 Howard Ave, 
New Haven, CT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Onyema Ogbuagu is an Infectious Disease provider in New Haven, Connecticut. Dr. Ogbuagu is rated as an Experienced provider by MediFind in the treatment of Kaposi Sarcoma. His top areas of expertise are HIV/AIDS, Myelitis, AIDS Dysmorphic Syndrome, AIDS Dementia Complex, and Endoscopy.

His clinical research consists of co-authoring 76 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Kaposi Sarcoma.

Specialties
Infectious Disease
Licenses
Internal Medicine in CT
Hospital Affiliations
Yale-New Haven Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 2 Less Insurance Carriers -

Locations

YALE UNIVERSITY
800 Howard Ave, New Haven, CT 06519
Other Locations
YALE UNIVERSITY
20 York St, New Haven, CT 06510

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 2b/3, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)
A Phase 2b/3, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)
Enrollment Status: Completed
Publish Date: October 15, 2025
Intervention Type: Drug
Study Drug: Leronlimab
Study Phase: Phase 2
A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months From a Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed
A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months From a Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed
Enrollment Status: Completed
Publish Date: June 04, 2024
Intervention Type: Drug
Study Drugs: Cabotegravir, Rilpivirine, BIKTARVY
Study Phase: Phase 3
A Phase III, Randomized, Multicenter, Open-label, Non-inferiority Study Evaluating the Efficacy, Safety and Tolerability of Switching to Dolutegravir/Lamivudine Fixed Dose Combination in HIV-1 Infected Adults Who Are Virologically Suppressed
A Phase III, Randomized, Multicenter, Open-label, Non-inferiority Study Evaluating the Efficacy, Safety and Tolerability of Switching to Dolutegravir/Lamivudine Fixed Dose Combination in HIV-1 Infected Adults Who Are Virologically Suppressed
Enrollment Status: Completed
Publish Date: October 19, 2023
Intervention Type: Drug
Study Drugs: Dolutegravir+Lamivudine, Current antiretroviral regimen
Study Phase: Phase 3
A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate Coronavirus Disease 2019 (COVID-19)
A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate Coronavirus Disease 2019 (COVID-19)
Enrollment Status: Completed
Publish Date: January 04, 2023
Intervention Type: Drug
Study Drug: Leronlimab
Study Phase: Phase 2
A Study of the Pharmacokinetic and Pharmacodynamic Interactions Between Bictegravir, Tenofovir Alafenamide and Rifapentine in Healthy Adult Subjects
A Study of the Pharmacokinetic and Pharmacodynamic Interactions Between Bictegravir, Tenofovir Alafenamide and Rifapentine in Healthy Adult Subjects
Enrollment Status: Withdrawn
Publish Date: September 20, 2021
Intervention Type: Drug
Study Phase: Phase 4
View 4 Less Clinical Trials

76 Total Publications

Drug-drug interactions in patients living with HIV who undergo solid organ transplant.
Drug-drug interactions in patients living with HIV who undergo solid organ transplant.
Journal: Expert opinion on drug metabolism & toxicology
Published: August 04, 2025
Similar Doctors
Gerald H. Friedland
Experienced in Kaposi Sarcoma
Dr. Gerald H. Friedland
Infectious Disease
Experienced in Kaposi Sarcoma
Dr. Gerald H. Friedland
Infectious Disease
15 York St, Nathan Smith Building, 
New Haven, CT 
 (0.1 miles away)
203-785-5303
Languages Spoken:
English
See accepted insurances

Gerald Friedland is an Infectious Disease provider in New Haven, Connecticut. Dr. Friedland is rated as an Advanced provider by MediFind in the treatment of Kaposi Sarcoma. His top areas of expertise are HIV/AIDS, Kaposi Sarcoma, COVID-19, and Severe Acute Respiratory Syndrome (SARS).

Experienced in Kaposi Sarcoma
Dr. Mark E. Lustberg
Infectious Disease
Experienced in Kaposi Sarcoma
Dr. Mark E. Lustberg
Infectious Disease

Yale University

800 Howard Ave, 
New Haven, CT 
 (0.1 miles away)
203-785-2140
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mark Lustberg is an Infectious Disease provider in New Haven, Connecticut. Dr. Lustberg is rated as an Advanced provider by MediFind in the treatment of Kaposi Sarcoma. His top areas of expertise are Cytomegalic Inclusion Disease, Cytomegalovirus Infection, HIV/AIDS, and Myelitis.

Experienced in Kaposi Sarcoma
Dr. Shiven B. Chabria
Infectious Disease | Hospital Medicine
Experienced in Kaposi Sarcoma
Dr. Shiven B. Chabria
Infectious Disease | Hospital Medicine

Prospect Ct Medical Foundation Inc

18 Haynes St, Uppr Level, 
Manchester, CT 
 (39.4 miles away)
860-649-7557
Languages Spoken:
English
See accepted insurances

Shiven Chabria is an Infectious Disease specialist and a Hospital Medicine provider in Manchester, Connecticut. Dr. Chabria is rated as an Experienced provider by MediFind in the treatment of Kaposi Sarcoma. His top areas of expertise are HIV/AIDS, Kaposi Sarcoma, Meningitis, Lymphangitis, and Ureteroscopy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ogbuagu's expertise for a condition
ConditionClose
    View All 18 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile